Aalto Bio Reagents, Dublin, Ireland, has released a native Dengue virus antigen for diagnostic test manufacturers, vaccine developers, and researchers globally. The native Dengue antigen is composed of intact virus particles made up of both structural and nonstructural proteins, including envelope and NS1. Dengue virus is a mosquito-borne flavivirus closely related to Zika virus and West Nile virus. The addition of the new native Dengue virus antigen offers access to vital new raw materials to test samples in the race to diagnose patients earlier and help with vaccine development. For more information visit Aalto Bio Reagents.
November 23, 2021
July 28, 2022
COVID-19: FDA Gives Flexibility to New York State Department of Health, Issues Emergency Use Authorization for Roche Diagnostic
March 13, 2020
January 15, 2021